| Drug Name: | Piroxicam (36322-90-4) |
|---|---|
| PubChem ID: | 54676228 |
| SMILES: | CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3 |
| InchiKey: | QYSPLQLAKJAUJT-UHFFFAOYSA-N |
| Therapeutic Category: | Analgesics, Anti-Inflammatory Agents, Antirheumatic Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Peripheral Nervous System Agents, Sensory System Agents |
| Molecular Weight (dalton) | : | 331.353 |
| LogP | : | 1.581 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 99.6 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Impairment Into Glycogen Metabolism | Glycogen synthase (P13807) | A decrease in the glycogen synthase in the active I form was time-dependent on piroxicam treatment The impairment into glycogen metabolism produced by piroxicam administration suggests liver becomes unable to maintain glucose homeostasis [ ADR Type 2 3 ] | Hepatic glycogen depletion in fed female rats induced by piroxicam |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category